According to the present invention, a combination of epigenetic factors and bispecific compounds targeted to CD33 and CD3 is proposed in the treatment of myeloid leukemia, where the epigenetic factor is selected from the group consisting of histone deacetylase (HDAC) inhibitors, DNA methyltransferase inhibitors, hydrochlorofluoride hydrochloride, cell inhibitors, hydrochlorofluoride leukemia, hydrophysic urethrase leukosis (HDM), hydrochlorofluoridine inhibitors, hydrophysic ureterans factor (G-CSF), histonemethylase inhibitors and ATRA (all-trans retinoic acid). Accordingly, according to the invention, a pharmaceutical composition is provided comprising a compound targeted to CD33 and at least one epigenetic factor, and an epigenetic factor for use in reducing the intensity and / or treatment of myeloid leukemia, where this epigenetic factor increases the patient's sensitivity to a compound targeted to CD33 . In addition, the invention provides the use of at least one epigenetic factor to increase the sensitivity of a patient with myeloid leukemia to treatment with a compound targeted to CD33, a method of treating myeloid leukemia, comprising administering to a patient in need of at least one epigenetic factor and compound, targeted to CD33, and a kit comprising a pharmaceutical composition of the invention or an epigenetic factor of the invention and a bispecific compound targeted to CD33.Согласно настоящему изобретению предложена комбинация эпигенетических факторов и биспецифических соединений, нацеленных на CD33 и CD3, в лечении миелоидного лейкоза, где эпигенетический фактор выбран из группы, состоящей из ингибиторов гистондеацетилазы (HDAC), ингибиторов ДНК-метилтрансферазы (DNMT) I, гидроксимочевины, гранулоцитарного колониестимулирующего фактора (G-CSF), ингибиторов гистондеметилазы и ATRA (полностью транс-ретиноевая кислота). Соответственно согласно изобретению предложена фармацевтическая композиция, содержащая соединение, нацеленное на CD33, и по меньшей м
